Is Non-Viral Gene Therapy About to Kill AAV?

YouTube Description: Non-viral gene delivery has always had one fatal flaw: it couldn't get DNA into the nucleus efficiently. LNPs top out at around 5% nuclear entry. SonoThera just hit 50% using ultrasound. Co-founder Ken Greenberg joins the show to break down exactly how they did it. We also cover AstroRx's embryonic stem cell-derived astrocyte therapy for MS, ANACA's TCR-T cell approach for solid tumors, Apligon's next-gen kinase inhibitor program, and Enterome's microbiome-based cancer therapy, plus the latest from the early stage biotech leaderboard at thebiotechvoyager.com. 0:00:00 Intro 0:00:51 Early Stage Biotech Leaderboard 0:02:20 Enterome: Microbiome Cancer Therapy 0:11:35 Ken Greenberg & SonoThera Preview 0:35:19 SonoThera Raises $125 Million 0:38:18 Apligon: Solid Tumor Kinase Inhibitors 0:44:34 ANACA: TCR-T Cell Therapy for Solid Tumors 1:00:34 AstroRx: Stem Cell Therapy for MS 1:02:43 Interview: Ken Greenberg, SonoThera 1:21:07 Sound Waves Delivering Gene Therapy 1:28:48 SonoThera Pipeline and Disease Targets New episodes every Tuesday and Thursday at 11:00 AM 🚀